Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Cancer patients with preexisting depression face a 24% higher risk of cancer-specific mortality, a large study found. But there's good news: early psychotherapy — within one week of diagnosis — was linked to a 27% lower mortality risk. The findings, presented at ASTRO 2024, highlight a critical gap in comprehensive cancer care.
Cancer patients dealing with depression before their diagnosis face a significantly higher risk of dying from their cancer, according to new research presented at the American Society for Radiation Oncology (ASTRO) annual meeting. The study, led by Dr. Edmund Qiao from UC San Diego, analyzed over 254,000 Medicare patients diagnosed with prostate, breast, colorectal, non-small cell lung, or bladder cancer between 2010 and 2017 — and found that the roughly 22% who had preexisting depression were at notably greater risk of cancer-specific death.
The silver lining? Timely mental health treatment made a real difference. Patients who received psychotherapy within one week of their cancer diagnosis saw a 27% reduction in cancer-specific mortality risk, while antidepressants were also associated with a modest but significant benefit. However, both effects weakened when treatment was delayed — and by 8 weeks, antidepressants showed no significant benefit at all.
By the Numbers:
Why it matters: With nearly two-thirds of depressed cancer patients going untreated in the critical weeks after diagnosis, this study makes a compelling case for routine mental health screening and rapid referral as a standard part of cancer care — not an afterthought.
